

3 September 2024

MARY HARNEY AS NON-EXECUTIVE DIRECTOR

INOVIQ Limited (ASX:IIQ) is delighted to announce the appointment of Mary Harney as a Non-Executive Director effective 1 October 2024.

Ms Harney is an experienced Non-Executive Director and Chief Executive and brings a deep understanding of applied life science research, in addition to experience in biopharmaceutical regulatory affairs and commercialisation. Ms Harney is the current Chair of Microbio Pty Ltd, an Australian biotech startup focused on changing the course of pathogen detection, and Oncology One, a biotech progressing a small molecule oncology pipeline. She was previously the Chair of Race Oncology (ASX: RAC), a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care.

IIQ Chairman David Williams said: *“We are extremely pleased Mary is joining the Board as she adds significant depth and breadth to the Board. We value her understanding of applied research, commercial, regulatory, pharmaceutical and biotechnology industries in a global setting. Mary joins at an important time as we develop and expand our cancer diagnostic tests and turn our exosome technology into powerful but elegant therapeutics.”*

Mary Harney said: *“I am delighted to be appointed to the board because cancer diagnostics and therapies are in my ‘sweet spot’ of interest and experience. I am very excited by the breadth of the possible applications for cancer diagnostics using exosomes. However, the ability to use exosomes as therapy is the real game changer and the real source of my interest.”*

Authorised by the Company Secretary, Mark Edwards.

FURTHER INFORMATION

David Williams

Chairman

E dwilliams@kidder.com.au

M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company pioneering next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit www.inoviq.com.

ABOUT MARY HARNEY *IDP-C BSC BA MAICD FIML IWF*

Mary completed the International Directors Program (IDP) offered by the prestigious INSEAD Business School in 2023. Mary was formerly the CEO of Royal Australasian College of Surgeons, CEO of Gardiner Research Foundation, COO and Director of Office of Cancer Research for Peter MacCallum Hospital and COO of Cerylid Biosciences. She has had other former roles with CSL, AMRAD, BIOPROPERTIES and Royal Melbourne Hospital.